An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Conjugated estrogens/medroxyprogesterone (Primary)
- Indications Menopausal syndrome
- Focus Pharmacokinetics
- Sponsors Wyeth
- 18 Nov 2006 New trial record.